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uchenne muscular dystrophy is an X-linked degener-
ative disorder of muscle caused by the absence of the
protein dystrophin. A major consequence of muscular
dystrophy is that the normal regenerative capacity of skeletal
muscle cannot compensate for increased susceptibility
to damage, leading to repetitive cycles of degeneration–
regeneration and ultimately resulting in the replacement
of muscle ﬁbers with ﬁbrotic tissue. Because insulin-like
growth factor I (IGF-I) has been shown to enhance muscle
regeneration and protein synthetic pathways, we asked
whether high levels of muscle-speciﬁc expression of IGF-I
in 
 
mdx
 
 muscle could preserve muscle function in the
diseased state. In transgenic 
 
mdx
 
 mice expressing 
 
mIgf-I
 
(
 
mdx:mIgf
 
 
 
/
 
 
 
), we showed that muscle mass increased by at
least 40% leading to similar increases in force generation in
D
 
extensor digitorum longus muscles compared with those
from 
 
mdx
 
 mice. Diaphragms of transgenic 
 
mdx:mIgf
 
 
 
/
 
 
 
exhibited signiﬁcant hypertrophy and hyperplasia at all
ages observed. Furthermore, the IGF-I expression signiﬁ-
cantly reduced the amount of ﬁbrosis normally observed
in diaphragms from aged 
 
mdx
 
 mice. Decreased myonecrosis
was also observed in diaphragms and quadriceps from
 
mdx:mIgf
 
 
 
/
 
 
 
 mice when compared with age-matched 
 
mdx
 
animals. Finally, signaling pathways associated with
muscle regeneration and protection against apoptosis
were signiﬁcantly elevated. These results suggest that a
combination of promoting muscle regenerative capacity
and preventing muscle necrosis could be an effective
treatment for the secondary symptoms caused by the primary
loss of dystrophin.
 
Introduction
 
The muscular dystrophies are degenerative disorders of
muscle where there is marked muscle weakness and fragility.
A subset of these diseases are caused by mutations in genes
encoding proteins of the dystrophin-associated glycoprotein
complex at the sarcolemma, and lead to its partial or complete
absence (for review see Campbell, 1995). The most common
form of the disease, affecting 1 out 3,500 newborn males,
is Duchenne muscular dystrophy in which dystrophin is
absent. Without the dystrophin complex to tether the actin
cytoskeleton inside the muscle cell to the extracellular matrix,
forces generated by the muscle fiber result in tears of the
sarcolemma and lead to muscle damage. The regenerative
capacity in muscle cannot compensate for increased susceptibil-
ity for structural damage. Therefore, a secondary consequence
in dystrophic muscle is the inability of the muscle to adequately
repair itself. The imbalance between muscle damage and
muscle repair leads to a loss of muscle fibers and an increase
in the amount of fibrosis over time until the functional
capacity of the muscle diminishes to a point below the required
force output.
Insulin-like growth factor I (IGF-I)* plays a critical role in
muscle regeneration. It promotes the proliferation and
differentiation of satellite cells in the muscle, enabling them
to fuse to existing muscle fibers and repair damaged regions
(Engert et al., 1996; for review see Florini et al., 1996). High
and constant levels of IGF-I also cause significant muscle
hypertrophy, which has been shown in numerous studies
where IGF-I has been infused, introduced by recombinant
virus, or overexpressed in transgenic animals (Adams and
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*Abbreviations used in this paper: EDL, extensor digitorum longus;
HGF, hepatocyte growth factor; IGF-I, insulin-like growth factor I; Lo,
optimum muscle length; 
 
mdx:mIgf
 
 
 
/
 
 
 
, transgenic 
 
mdx
 
 mice expressing
 
mIgf-I
 
;
 
 mIgf
 
 
 
/
 
 
 
, transgenic mice expressing 
 
mIgf-I
 
; P-Akt, phosphorylated
Akt; PI3K, phosphoinositol 3-kinase; PKB or Akt, protein kinase B. 
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McCue, 1998; Barton-Davis et al., 1998; Coleman et al.,
1995; Lynch et al., 2001; Musaro et al., 2001). In addition,
muscle enlargement in these animals results in an increased
capacity of force generation. In aging-related declines in
muscle mass and strength, it is thought that a significant fac-
tor is an impaired regenerative capacity (Barton-Davis et al.,
1998; Musaro et al., 2001). IGF-I enhances regenerative ca-
pacity via the stimulation of satellite cell proliferation and
differentiation. Furthermore, IGF-I promotes protein syn-
thetic pathways (Russell-Jones et al., 1994; Adams and Mc-
Cue, 1998), which can override muscle degeneration.
Because it is clear that IGF-I can prevent aging-related loss
of muscle function (Barton-Davis et al., 1998; Renganathan
et al., 1998), it is possible that IGF-I can prevent or dimin-
ish muscle loss associated with disease. Although the pres-
ence of IGF-I can do nothing for the primary defect in mus-
cular dystrophy, it is possible that significant benefit might
be derived from defending against the secondary symptoms
associated with the disease. IGF-I could induce functional
hypertrophy in muscle that is inherently weak. First, IGF-I
could enhance muscle regenerative capacity to offset the im-
balance between muscle damage and repair. Second, IGF-I
could promote protein synthetic pathways and prevent mus-
cle-wasting pathways. The combined effect of enhanced re-
pair and decreased wasting might lead to greater functional
capacity over time, where there is a reduction in the propor-
tion of maximal effort needed to produce a required force,
so the muscle is less likely to be damaged by normal activity.
Using the 
 
mdx
 
 mouse, a naturally occurring animal model
for Duchenne muscular dystrophy (Sicinski et al., 1989), we
asked if overexpression of IGF-I would promote muscle repair
mechanisms and improve the dystrophic condition. Although
not as severe as the 
 
mdx:utr
 
 
 
/
 
 
 
 mouse (Deconinck et al.,
1997), muscles from the 
 
mdx
 
 mouse exhibit critical hallmarks
of the human form of the disease, including a high suscepti-
bility to contractile-induced damage, a significant degree of
muscle fiber degeneration and regeneration, and increased fi-
brosis later in life (Anderson et al., 1987; Carnwath and Shot-
ton, 1987). The diaphragm of the 
 
mdx
 
 mouse, in particular,
displays a Duchenne-like phenotype (Stedman et al., 1991).
To introduce IGF-I into the 
 
mdx
 
 animals, we crossbred them
with a recently characterized transgenic mouse that expresses
high levels of IGF-I in muscle (Musaro et al., 2001). IGF-I
transgene expression is restricted to muscle by using the myo-
sin light chain 1/3 promoter; the mice exhibit significant mus-
cle hypertrophy with no adverse side effects as well as en-
hanced regenerative capacity in aging muscle (Musaro et al.,
2001). This approach allowed for the assessment of the maxi-
mum potential benefit that could be derived from IGF-I ex-
pression for dystrophic muscle, as well as examination of both
the diaphragm and the extensor digitorum longus (EDL),
which display a spectrum of dystrophic pathologies. By ana-
lyzing both muscle morphology and function in transgenic
IGF/
 
mdx
 
 crosses (transgenic 
 
mdx
 
 mice expressing 
 
mIgf-I
 
[
 
mdx:mIgf
 
 
 
/
 
 
 
]), we observed significant improvement in mus-
cle mass and strength, a decrease in myonecrosis, and a reduc-
tion in fibrosis in aged diaphragms.
 
Results
 
Morphology
 
A chemiluminescent assay was used to determine the
amount of IGF-I in muscles from all strains. IGF-I content
in muscles from transgenic mice expressing 
 
mIgf-I
 
 (
 
mIgf
 
 
 
/
 
 
 
and 
 
mdx:mIgf
 
 
 
/
 
 
 
) doubled compared with 
 
mdx
 
 and control
animals (Table I). This level of IGF-I was sufficient to pro-
Figure 1. Hemotoxilin and eosin histology of young (3 mo) EDLs. 
Images reveal the fiber hypertrophy in both mIgf
 /  strains, and that 
central nuclei remain in mdx:mIgf
 /  in similar proportions to mdx 
muscle. (A) mdx; (B) mdx:mIgf
 /  ; (C) control; (D) mIgf
 / . Bar,
50  m.
 
Table I. 
 
Animal and muscle masses in control, 
 
mIgf
 
 
 
/
 
 
 
, 
 
mdx
 
, and 
 
mdx:mIgf
 
 
 
/
 
 
 
 
 
mice
Strain Control
 
mIgf
 
 
 
/
 
 
 
mdx mdx:mIgf
 
 
 
/
 
 
 
Muscle IGF-I (ng/g) 9 
 
 
 
 1 16.2 
 
 
 
 2
 
a
 
8 
 
 
 
 0 14 
 
 
 
 1
 
a,b
 
Body weight (g) 24.7 
 
 
 
 0.1 35.5 
 
 
 
 0.3
 
a
 
33.1 
 
 
 
 0.8
 
a
 
40.0 
 
 
 
 0.7
 
a,b
 
Quadriceps (mg) 214.4 
 
 
 
 8.7 312.7 
 
 
 
 29.9
 
a
 
291.7 
 
 
 
 11.8
 
a
 
380.4 
 
 
 
 9.8
 
a,b
 
Tibialis anterior (mg) 51.9 
 
 
 
 0.9 74.1 
 
 
 
 0.1
 
a
 
79.6 
 
 
 
 1.2
 
a
 
114.2 
 
 
 
 3.3
 
a,b
 
EDL (mg) 10.2 
 
 
 
 0.2 12.7 
 
 
 
 0.5
 
a
 
15.7 
 
 
 
 0.4
 
a
 
25.6 
 
 
 
 0.5
 
a,b
 
Soleus (mg) 9.2 
 
 
 
 0.3 8.8 
 
 
 
 0.5 14.9 
 
 
 
 0.2
 
a
 
14.8 
 
 
 
 0.3
 
a
 
Heart (mg) 128.4 
 
 
 
 4.5 125.5 
 
 
 
 2.2 126.8 
 
 
 
 5.5 119 
 
 
 
 7.8
Data represent mean 
 
 
 
 SEM for muscles from four mice, aged 3 mo. Muscle IGF-I was determined from acetic acid extracts (D’Ercole et al., 1984) of limb
muscle by Quest Diagnostics. 
 
a
 
Statistically significant compared to C57Bl/6 controls, 
 
P
 
 
 
 
 
 0.05. 
 
b
 
Statistically significant compared to 
 
mdx
 
 controls, 
 
P
 
 
 
 
 
 0.05.  
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mote increased muscle size in the transgenic animals. Mus-
cles from 
 
mdx mice show significant hypertrophy when
compared with nondystrophic muscles. The addition of
muscle-specific IGF-I expression in mdx muscle caused sig-
nificant hypertrophy over and above that normally found in
these animals (Table I and Fig. 1). Muscle mass was in-
creased by  63% in EDL muscles from young mdx:mIgf
 / 
mice as compared with those from mdx mice, and was main-
tained at this level through at least 1 yr of age (Fig. 2). This
hypertrophy was greater than that measured in the EDL
muscles from the mIgf
 /  animals, where there was a 40%
increase in muscle mass compared with nontransgenic con-
trols (Table I) (Musaro et al., 2001). Muscles that expressed
the transgene at very low levels, as in the soleus, or did not
express the transgene at all, such as the heart, displayed no
significant hypertrophy when compared with nontransgenic
mdx tissues (Table I).
EDL muscles were further analyzed to determine the
source of the increased mass. A combination of hypertrophy
of the muscle fibers and an increase in fiber number contrib-
uted to the higher weights of the EDLs from young mdx:
mIgf
 /  animals (Fig. 3, A and B). Fiber numbers followed
the following trend: mdx:mIgf
 /    mdx   IGF
 /    con-
Figure 2. Hemotoxilin and easin histology of aged (14 mo) EDLs. 
mdx (A and C) and mdx:mIgf
 /  (B and D) mice. Igf-I expression 
preserves mdx muscle homogeneity and promotes muscle
hypertrophy. Bars: (A and B) 100  m; (C and D) 50  m.
Figure 3. Fiber analysis of EDL muscles. (A) The number of fibers 
in the midbelly cross section of young EDL muscles was significantly 
higher in mdx:mIgf
 /  muscles compared with mdx muscles. By 14 
mo of age, however, the difference in fiber number disappeared. (B) 
Fiber size distribution in young EDL muscles. There was a rightward 
shift indicative of an increase in fiber area in young mdx:mIgf
 /  
muscles compared with mdx muscles. (C) Fiber size distribution in 
aged EDL muscles. The increase in fiber area was also observed in 
EDL muscles from 14-mo-old mdx:mIgf
 /  animals. However, the 
distribution of fiber sizes in older muscles from both strains was
significantly wider compared with younger muscles. (D) Fiber type 
distribution of mdx and mdx:mIgf
 /  EDL muscles. Young EDL
muscles displayed no shift in fiber type composition with IGF-I 
expression. However, the decline in the IIb fiber population associated 
with older mdx EDLs was prevented in EDLs from mdx:mIgf
 /  
mice. *, statistically significant from young mdx EDL, P   0.05.140 The Journal of Cell Biology | Volume 157, Number 1, 2002
trol. Therefore, IGF-I increased the hyperplasia normally
observed in mdx muscle, an effect that differed from the re-
sponse of control muscle to high levels of IGF-I. However,
by 14 mo of age, the increase in fiber number in mdx:mIgf
 / 
EDL muscles disappeared, and the increased muscle size was
solely due to hypertrophy of the muscle fibers (Fig. 3, A and
C). Fiber type distribution, as assessed by immunostaining
with antibodies recognizing types I, IIa, and IIb and embry-
onic myosin heavy chains, was not affected by IGF-I expres-
sion in young (3 mo old) EDL muscles. As mdx mice age,
the continuous cycles of degeneration and regeneration lead
to an increase in the heterogeneity of fiber size and a loss of
fast fiber types (Anderson et al., 1987). An examination of
14-mo-old EDL muscles from mdx:mIgf
 /  mice showed
that the distribution of fiber type was preserved, compared
with those from mdx animals (Fig. 3 D).
The EDL is an infrequently used muscle in a cage-reared
mouse, and thus does not provide a rigorous test for the po-
tential of IGF-I to counter dystrophin loss. The heavy de-
mand on the mouse diaphragm makes it a more appropriate
model for the human dystrophies especially in the mdx back-
ground. By 1 yr of age in the mdx mouse, the diaphragm dis-
plays dramatically increased fibrosis and functional loss (Sted-
man et al., 1991). Thus, the diaphragm was examined in 3- and
14-mo-old mdx:mIgf
 /  mice. These results were more dra-
matic than those found in limb muscles. Young mdx:mIgf
 / 
diaphragms were significantly thicker than mdx controls,
which was due to a combination of increased fiber size
and number (Figs. 4 and 5). The number of fibers in the sag-
ittal plane of the diaphragm significantly increased in young
mdx:mIgf
 /  animals (Fig. 5 A). There was also an increase in
fiber size, as shown by the rightward shift in the fiber size dis-
tribution (Fig. 5 B). The response to IGF-I was amplified in
the diaphragms of old mice, which tripled in thickness when
compared with diaphragms from mdx controls (Fig. 5 A and
Figure 4. Histology of young diaphragms from control, mIgf
 / , 
mdx, and mdx:mIgf
 /  mice. Diaphragms from 3-mo-old mdx:
mIgf
 /  animals (D) were  60% thicker than age-matched mdx
control diaphragms (B). There was modest hypertrophy in young 
mIgf
 /  diaphragms (C) compared with controls (A), but due only to 
increased fiber size not to an increase in fiber number.
Figure 5. Fiber analysis of diaphragms. (A) The number of fibers 
across the sagittal plane of the mdx:mIgf
 /  diaphragm was almost 
double that of other strains at 3 mo of age, and by 14 mo, there 
were approximately three times as many fibers when compared 
with age-matched diaphragms from the other mouse strains. (B) 
Fiber size increased in young mdx:mIgf
 /  diaphragms as the 
proportion of larger fibers was greater than in mdx diaphragms. (C) 
By 14 mo, there was a leftward shift in fiber size distribution in the 
mdx:mIgf
 /  diaphragms. Thus, the increased thickness of young 
mdx:mIgf
 /  diaphragms was due to a combination of hyperplasia 
and fiber hypertrophy, whereas the increased size of aged mdx:
mIgf
 /  diaphragms was due primarily to hyperplasia. *, statistically 
significant from mdx diaphragm, P   0.05.Transgenic IGF-I expression in mdx mice | Barton et al. 141
Fig. 6). In contrast to the young diaphragms, hyperplasia was
the primary source for the increased size in the mdx:mIgf
 / 
diaphragms (Fig. 5 A), as there was no rightward shift in fiber
size distribution (Fig. 5 C).
One of the hallmark symptoms of muscular dystrophy is
increased fibrosis later in life. We used Gomori trichrome
staining and hydroxyproline measurements to assess the level
of fibrosis in 14-mo-old diaphragms. The replacement of
muscle fibers by fibrotic tissue was prevented by IGF-I ex-
pression. In aged diaphragms, collagen content was main-
tained at normal levels (Fig. 6, C and D, and Fig. 7).
Functional analysis
Even though dystrophic muscles are larger than normal
healthy muscles, the increased muscle mass has impaired
strength due to a reduction in the force per cross-sectional
area (specific force). Analysis of the force-generating capacity
in the EDLs from young mdx:mIgf
 /  animals showed that
the increase in muscle size produced a proportional increase
in force, although the specific force was uncorrected (Table
II). The cross-sectional area (Brooks and Faulkner, 1988) of
EDL muscles from mdx:mIgf
 /  animals was 49   6%
greater than nontransgenic mdx EDLs. A comparable in-
crease in tetanic force was also observed; transgenic EDLs
generated 37  16% more force than muscles from nontrans-
genic animals. This trend held in aged EDLs, where muscle
hypertrophy and comparable increases in muscle force were
also observed. The specific force of these muscles, however,
was similar to that of dystrophic muscles (Table II). Thus the
mdx:mIgf
 /  muscle increases functional capacity by increas-
ing muscle mass, but not by increasing specific force.
It is possible that this increase in the absolute force–gener-
ating capacity of the mdx:mIgf
 /  muscles affords protection
against contractile damage, because less muscle mass will be
needed to produce a given amount of force and work. Thus,
either the number of fibers recruited and/or the recruitment
frequency may be lower in the mdx:mIgf
 /  as compared with
either mdx or normal muscle. This is illustrated in Fig. 8. The
maximum force generated by mdx or C57 EDLs at 120 Hz,
which was the fusion frequency under our conditions, is
comparable to the force generated in mdx:mIgf
 /  muscles
stimulated at only 70–80 Hz (Fig. 8 A, dotted line). Reduced
relative load on the muscle may result in less damage being
incurred during routine use of the muscles. To demonstrate
that this is the case for the mdx:mIgf
 /  cross, eccentric con-
tractions were performed at equivalent forces (mdx:mIgf
 /  at
80 Hz vs. mdx and C57 at 120 Hz) and equivalent recruit-
ment frequencies (80 Hz for all strains). The results of this
experiment are shown in Fig. 8 B. The decrement of force be-
tween the first and fifth contractions in muscles from mdx
and mdx:mIgf
 /  animals was similar at equivalent stimula-
tion frequencies (34.5   9.8% vs. 37.3   8.7% for mdx and
mdx:mIgf
 / , respectively). However, when muscles were
subjected to eccentric contractions at equivalent forces (Fig. 8
B, right), mdx muscles experienced significantly greater drops
in force (37.3   8.7% for mdx:mIgf
 /  at 80 Hz vs. 64.3  
3.4% for mdx at 120 Hz). Muscles from C57 animals in-
curred minimal damage at either stimulation frequency (Fig.
8 B). Thus, although susceptibility to contractile damage is
still present in mdx:mIgf
 /  muscles, the fact that a reduced
proportion of the transgenic muscle is required for the gener-
ation of equivalent force, compared with mdx muscles, re-
duces the potential for damage.
Further evidence for a reduction of myonecrosis in mdx:
mIgf
 /  animals is found in muscles from Evan’s blue dye–
injected mice (Fig. 9) (Straub et al., 1997). Both the quadri-
ceps and the diaphragm from mdx:mIgf
 /  animals show sig-
nificantly less dye uptake than the same muscles from mdx
animals. As an indicator of whole animal muscle damage,
Figure 6. Histology of aged (14 mo) diaphragms. 
In 14-mo-old animals, the hypertrophic response 
continued; the thickness of mdx:mIgf
 /  diaphragms 
(B) were triple that of mdx controls (A). Gomori’s 
trichrome staining (C and D) revealed a reduction 
in connective tissue in mdx:mIgf
 /  diaphragms (D) 
compared with those from mdx controls (C). Bars, 
50  m.
Figure 7. Hydroxyproline content of aged diaphragm muscles. 
Hydroxyproline levels, an index of fibrosis, were reduced in
14-mo-old mdx:mIgf
 /  diaphragms to normal levels found in 
age-matched mIgf
 /  and control muscles. Measurements were 
performed in duplicate on n   2 muscle samples from each mouse 
strain. *, statistically significant (P   0.05) from age-matched 
control diaphragm.142 The Journal of Cell Biology | Volume 157, Number 1, 2002
serum creatine kinase measurements were performed on
3-mo-old animals. There is a 40% decrease in serum cre-
atine kinase levels in mdx:mIgf
 /  animals compared with
mdx controls (472   60 U/L vs. 839   121 U/L, respec-
tively, for n   6 mice), and these levels are indicative of a re-
duction in contractile damage for the whole animal.
Activation of Akt
Protein kinase B (PKB or Akt) activation has been shown to
be a major component of how IGF-I mediates cell survival
and growth in muscle (Alessi and Cohen, 1998; Lawlor and
Rotwein, 2000a; Wu et al., 2000). To examine if IGF-I acti-
vated this pathway in the transgenic animals, we measured
the level of Akt phosphorylation as an indicator of pathway
activation. Results of these measurements are shown in Fig.
10. Akt phosphorylation was dramatically higher in mdx:
mIgf
 /  muscle compared with all other strains studied. To-
tal Akt protein was modestly higher in mdx, mIgf
 / , and
mdx:mIgf
 /  compared with wild-type muscle, but not high
enough to account for the increase in Akt activation. Sur-
prisingly, Akt phosphorylation in mIgf
 /  muscle did not
differ from control tissue. However in mdx:mIgf
 /  muscle,
the drive for regeneration remains high throughout the life
of the animal, and the pathways by which fiber regeneration
is regulated, including the phosphoinositol 3-kinase (PI3K)/
Akt pathway, also remain active.
An additional contribution to the improved status of mdx:
mIgf
 /  muscle may arise from the anti-apoptotic properties
of IGF-I (Lawlor and Rotwein, 2000a,b). These effects have
been shown to be mediated via the PI3K pathway (involving
Akt activation) in a number of cell types, including muscle
(Lawlor and Rotwein, 2000b; Wu et al., 2000). A height-
ened level of apoptosis has been observed in mdx muscle,
possibly due to calcium overload from sarcolemmal damage
or perforin-mediated cytotoxicity (Spencer et al., 1997; San-
dri et al., 1998; Sandri and Carraro, 1999). Although we ob-
served a low level of apoptosis in mdx muscles ( 0.5%; un-
published data), the dynamic range between normal and
dystrophic tissue was too small to enable direct detection of
any anti-apoptotic effect of IGF-I in mdx:mIgf
 /  animals.
However, there is the clear potential to enhance protection
against apoptosis via increased Akt activation.
Discussion
The major findings of this study all indicate that muscle-spe-
cific expression of IGF-I can counter aspects of the muscular
dystrophy associated with the loss of dystrophin. The effects
Table II. Contractile properties of EDL muscles from 3-mo-old mice
Strain Control mIgf
 /  mdx mdx:mIgf
 / 
Cross-sectional area (mm
2) 1.93   0.05 2.33   0.01
a 2.27   0.06
a 3.38   0.06
a,b
Tetanic force (mN) 406.3   16.7 595   6.5
a 352   20
a 482   26
a,b
Specific force (N/cm
2) 21.0   0.8 25.5   0.3
a 15.4   0.7
a 14.3   0.8
a
Data represent mean   SEM for muscles from four mice for each strain. Cross-sectional area was determined using the methods of Brooks and Faulkner
(1988). 
aStatistically significant compared to C57Bl/6 controls, P   0.05. 
bStatistically significant compared to mdx controls, P   0.05.
Figure 8. Functional assessment of EDLs from mdx and mdx:
mIgf
 /  mice. (A) Force frequency relationship of EDL muscles. 
The maximum force generated by control and mdx EDLs at 120 
Hz is comparable to the force generated in mdx:mIgf
 /  muscles 
stimulated at  70–80 Hz (dotted line). Eccentric contractions 
were performed at equivalent forces (mdx:mIgf
 /  at 80 Hz vs. mdx 
and control at 120 Hz) and at equivalent stimulation frequencies 
(dashed line, 80 Hz for all strains). (B) Damage associated with
eccentric contractions in mdx, mdx:mIgf
 / , and control EDLs. (B, 
left) EDL muscles were subjected to five eccentric contractions 
with a 10% Lo stretch during stimulation at 80 Hz. The decrement 
of force between the first and last contraction is not significantly 
different between mdx and mdx:mIgf
 /  muscle at this stimulation 
frequency (34.5   9.8% vs. 37.3   8.7% for mdx and mdx:
mIgf
 / , respectively), and both are more susceptible to damage 
than control muscles. (B, right) When muscles were subjected to
eccentric contractions at equivalent force, mdx muscles experi-
enced significantly greater drops in force (37.3   8.7% for mdx:
mIgf
 /  at 80 Hz vs. 64.3   3.4% for mdx at 120 Hz, P   0.05). 
Control muscles were not susceptible to contraction-induced
injury at 120-Hz stimulation frequency. *, statistically significant 
(P   0.05) from age-matched mdx muscles.Transgenic IGF-I expression in mdx mice | Barton et al. 143
of IGF-I result in muscle hypertrophy, increased muscle
strength (albeit with low specific force), decreased myone-
crosis, and reduced muscle fibrosis. In contrast to the effects
of IGF-I in transgenic mice, where expression of IGF-I regu-
lated by a different muscle-specific promoter resulted in car-
diac hypertrophy and elevated plasma levels of IGF-I (De-
laughter et al., 1999), we did not see any deleterious effects
on the heart. This is most likely due to the lower levels of
IGF-I produced by the myosin light chain 1/3 promoter
construct. There is  20 times more IGF-I protein in the
transgenic lines previously described (Coolican et al., 1997).
This suggests that a small increase in local IGF-I production
is sufficient to drive muscle hypertrophy. As we previously
showed (Barton-Davis et al., 1998; Musaro et al., 2001), the
IGF-I levels in the blood were not elevated and there was no
effect seen in muscles that did not express the transgene.
Furthermore, the affected muscles were not only hypertro-
phied, but maintained a uniformity of fiber size and type
distribution, compared with muscles from mdx animals (Fig.
4). We propose that long-term IGF-I expression results in
IGF-I–driven enhancement of the repair mechanisms that
direct satellite cell activation, proliferation, and differentia-
tion so that fiber degeneration does not go unchecked.
IGF-I is a potent signal for growth in a number of tissues.
Limiting its expression to muscle by driving it with a fast
muscle-specific promoter and using an isoform that does not
enter the circulation enables skeletal muscle to be the sole
target of IGF-I activity (Musaro et al., 2001). However, be-
cause skeletal muscle is comprised of multiple cell types,
IGF-I secreted from muscle fibers could stimulate other cells
in addition to muscle fibers and satellite cells. Fibroblasts, in
particular, are responsive to IGF-I (Petley et al., 1999) and
are the source of the increased collagen deposition seen in
dystrophic muscles. In the transgenic mouse that overex-
presses human IGF-I, fibrosis was observed in the heart in
animals over 1 yr of age (Delaughter et al., 1999), confirm-
ing the possibility that in our model, IGF-I would drive fi-
brosis as well. Even though IGF-I has been shown to stimu-
late fibroblasts, there is a net decrease in fibrosis in
diaphragms of the mdx:mIgf
 /  mice. In fact, age-related fi-
brosis in the mdx diaphragm was effectively eliminated by
IGF-I expression (Figs. 6 and 7). It may be that the efficient
and rapid repair of the mdx:mIgf
 /  muscles prevents the es-
tablishment of an environment into which the fibroblasts
migrate. This is of particular relevance to the human dystro-
phic condition where virtually all skeletal muscles succumb
to fibrosis (Louboutin et al., 1993; Morrison et al., 2000).
Thus, the results found in the mouse diaphragm suggest that
IGF-I might be effective not only in increasing muscle mass
and strength, but also in reducing fibrosis associated with
the disease.
The effect of IGF-I on other tissues might also contribute
to the preservation of fiber type in the older animals. When
muscle fibers are severely damaged and lose innervation, it
has been shown that slow motor neurons are more apt to
reinnervate the regenerated fibers (Desypris and Parry,
1990). Given that neurons also respond to IGF-I, it is possi-
ble that the difference in reinnervation properties is mini-
mized in these animals. Alternatively, the muscle repair
mechanisms, which are enhanced by the presence of IGF-I
(Musaro et al., 2001), might aid in muscle repair without
the occurrence of degeneration. Although we have not di-
rectly tested these possibilities, the lower degree of myone-
crosis apparent in mdx:mIgf
 /  muscle shows that there is
less degeneration, and so perhaps less denervation. However,
this observation does not exclude the potential effect on mo-
tor neurons.
The aged mdx diaphragm normally demonstrates a
marked loss of fiber number (Stedman et al., 1991). How-
ever, in the aged mdx:mIgf
 /  diaphragms, profound hyper-
plasia was observed. This suggests that the satellite cell pool
in dystrophic tissue is not depleted over time, but instead,
the signals that activate the regeneration diminish. With suf-
ficient stimulation by exogenous IGF-I, the satellite cell pro-
liferation more than compensates for the need for fiber re-
generation. In normal muscle, the replicative capacity of
satellite cells is sufficient to maintain muscle mass as long as
existing muscle fibers can generate the appropriate signals
for activating them (Allen et al., 1995; Chakravarthy et al.,
2000a). With aging, we and others have proposed that the
limiting factor in muscle regeneration is the availability of
Figure 9. Evan’s blue staining on cryosections from young (3 mo) 
mdx and mdx:mIgf
 /  muscles. 10- m cryosections from mdx (A 
and B) and mdx:mIgf
 /  (C and D) mice. Quadriceps (A and C) and 
diaphragms (B and D). Bar, 100  m.
Figure 10. Immunoblot analysis of total Akt, P-Akt, and  -tubulin 
in quadriceps muscles from 3-mo-old control (wt), mIgf
 / , mdx, 
and mdx:mIgf
 /  mice. Akt phosphorylation of both serine 473 and 
threonine 308 was significantly amplified in mdx:mIgf
 /  muscle, 
without a commensurate change in total Akt levels compared with 
muscles from mIgf
 /  and mdx strains. Immunoblotting for  -tubulin 
served as a control for protein loading.144 The Journal of Cell Biology | Volume 157, Number 1, 2002
growth and repair-inducing growth factors, including IGF-I
and hepatocyte growth factor (HGF) (Barton-Davis et al.,
1998; Chakravarthy et al., 2000b; Musaro et al., 2001). Sat-
ellite cells extracted from aged muscle can still respond to
these factors if they are provided (Allen et al., 1995; Chakra-
varthy et al., 2000a). However, it is unclear what the limit-
ing factor is in dystrophic muscle. Studies have shown that
the mitotic potential of satellite cells from young muscular
dystrophy patients is comparable to that found in human se-
nescence, suggesting that the heightened necessity for mus-
cle repair associated with muscular dystrophy could eventu-
ally deplete the pool of satellite cells (Decary et al., 2000).
Although we have not examined muscles from extremely old
mdx:mIgf
 /  mice at this time, the observations of the 14-
mo-old diaphragms support the hypothesis that the satellite
cell pool is not depleted in dystrophic muscle and readily re-
sponds to increased levels of IGF-I.
Telomere length proves to be an excellent indicator of the
number of divisions that a group of cells has undergone
(Harley, 1997; Wright and Shay, 2000). A number of stud-
ies have shown that telomere length in human dystrophic
muscle is significantly reduced compared with samples from
healthy muscle (Decary et al., 1997, 2000). In mice, how-
ever, the number of base pairs lost per division is minimized
by telomerase activity, which tends to maintain telomere
length even after several divisions, thereby obscuring the
correlation between replicative age and telomere length
(Prowse and Greider, 1995; Wright and Shay, 2000).
Therefore, although telomere length could provide some
measure of whether IGF-I is depleting a satellite pool by
driving proliferation, this question cannot be pursued in the
mouse. If, however, IGF-I treatment is to become a reality
in human disease, it will be essential to address this issue.
The effect of IGF-I on fiber number in mdx mice differs
from the effect in normal mice. Under healthy conditions,
activated satellite cells proliferate and fuse to existing fibers,
or in the case of a damaged fiber, fuse to each other to form a
new fiber within the basal lamina of the old one. In patho-
logic conditions, such as muscular dystrophy, perhaps the in-
creased drive for satellite cell activation results in increased
numbers of fibers, as has been shown in culture (Engert et
al., 1996). Hyperplasia in the mdx:mIgf
 /  muscles was exac-
erbated, particularly in the diaphragm (Figs. 4 and 6). This
suggests that there may be some threshold level of satellite
cell activation and/or muscle damage beyond which stimu-
lated satellite cells begin to fuse with each other and form
new fibers, in addition to fusing to existing damaged fibers.
It is unclear which factors involved in the proliferation
and differentiation of satellite cells drive the regenerative
process toward new fiber formation. Because IGF-I can reg-
ulate both processes, the levels or activation of additional
factors that affect the ultimate outcome of the signaling
pathways likely differ in mdx muscle. Possible factors in-
clude HGF, fibroblast growth factor, and myostatin, a mus-
cle-specific member of the TGF-  superfamily (McPherron
et al., 1997). Myostatin has been shown to block myoblast
proliferation in vitro (Thomas et al., 2000), whereas HGF
and fibroblast growth factor are involved in the activation
and proliferation of satellite cells (Sheehan and Allen, 1999).
Muscles from myostatin-null mice exhibit an increase in fi-
ber size and number (McPherron et al., 1997). Thus, a
change in the activation levels of any of these factors could
contribute to the modest hyperplasia seen in the mdx mice,
and, in combination with IGF-I, may contribute to the pro-
found hypertrophy in the mdx:mIgf
 /  mice. Other investi-
gators have shown that, in muscle, activation of the MAPK
cascade leads to the proliferation of cells (Coolican et al.,
1997; Samuel et al., 1999). Therefore, the interaction of
other factors with this arm of IGF-I activation would result
in the differing effects of IGF-I in normal and dystrophic
muscle. Either a reduction in the inhibition or an enhance-
ment of activation of the MAPK pathway could lead to a
greater proliferative response in the mdx:mIgf
 /  cross as
compared with the mdx only or the mIgf
 /  animals. Al-
though we have not examined the interactions between IGF-I
and other growth factors in normal or dystrophic muscle at
this time, these animals could serve as ideal models for
studying the intracellular responses to these growth factors.
IGF-I also promotes cell survival, primarily through the
PI3K pathway and Akt activation (Alessi and Cohen, 1998;
Lawlor and Rotwein, 2000b). Cell culture studies have con-
firmed that the presence of IGF-I drives the PI3K pathway,
particularly at the inception of differentiation (Musaro and
Rosenthal, 1999; Chakravarthy et al., 2000a). Because height-
ened levels of apoptosis have been documented in dystrophic
muscle (Spencer et al., 1997; Sandri et al., 1998; Sandri and
Carraro, 1999), the activation of cell survival pathways dur-
ing the regenerative process might provide some protection
against cell death. Alternatively, amplified Akt phosphoryla-
tion in mdx:mIgf
 /  muscle might only be reflective of the
increased drive for fiber regeneration and differentiation.
Recent work has identified Akt1 (PKB ) as the predomi-
nant isoform involved in cell survival, and Akt2 (PKB ) as
the primary player in differentiation (Vandromme et al.,
2001). In this study, no distinction was made between the
amount of phosphorylation of specific Akt isoforms. We can
conclude that cell survival pathways are indeed heightened
in mdx:mIgf
 /  muscle. Further measurements are necessary
to examine the Akt2/differentiation pathway.
One of the major consequences of the loss of dystrophin in
muscle is a high susceptibility to contractile damage. As
stated previously, IGF-I can do nothing directly to prevent
this. However, the combined effect of increased strength and
enhanced repair can indirectly counteract contractile dam-
age. This might lead to greater functional capacity over time
and extend the period during which dystrophic muscle is
functional. There is a reduction in the proportion of maxi-
mal effort needed to produce a required force, so the muscle
is less likely to be damaged by normal activity. The most
damaging type of activity is eccentric contraction, where
there is a very high strain imposed on the connections be-
tween the extracellular matrix and the cytoskeleton. In our
experiments, assessment of the amount of damage incurred
by eccentric contraction shows that mdx:mIgf
 /  EDL mus-
cles are just as susceptible to damage as muscles from mdx
mice, but only when they are stimulated to achieve equiva-
lent strain (same stimulation frequency). The more critical
observation in this case is the comparison of contractile dam-
age incurred at equivalent forces. As shown if Fig. 8, having
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against damage when generating a given level of force. The
benefit of more muscle in the mdx:mIgf
 /  mice is also sup-
ported by the 40% reduction in serum creatine kinase levels.
Increased myofiber degeneration and necrosis is associated
with many of the muscular dystrophies. We have observed a
marked decrease in myonecrosis by Evan’s blue staining in
muscles from the mdx:mIgf
 /  animals (Fig. 9), as well as a
decrease in serum creatine kinase levels. These results suggest
that IGF-I is promoting growth pathways sufficiently to off-
set the normal damage that is found in mdx muscle. Cer-
tainly, the increased phosphorylated Akt (P-Akt) levels serve
as indicators for increased growth and survival. In addition to
promoting growth pathways, enhanced regeneration caused
by IGF-I (Musaro et al., 2001) acts in a complementary man-
ner by repairing existing damage. These results show that on
the whole animal level, IGF-I–driven functional hypertrophy
of dystrophic muscle has therapeutic promise.
In summary, dystrophic muscles display a high susceptibil-
ity to contractile damage, increased cycles of degeneration
and regeneration, a progressive decline in strength, and in-
creased fibrosis later in life. The therapies being contemplated
to treat the disease are generally directed at correction of the
primary defect, the loss of dystrophin (Hartigan-O’Connor
and Chamberlain, 2000; Rando et al., 2000; Wang et al.,
2000). However, the sheer size of the dystrophin cDNA and
the need to deliver the cDNA to all muscle cells throughout
the body limit the ability of gene therapy techniques used for
dystrophin replacement. An alternative strategy is to treat the
secondary symptoms of the disease using a secreted growth
factor that would have its effect on all of the fibers of a mus-
cle, even if only a subset of the fibers received gene transfer.
Through a number of different studies of normal muscle,
IGF-I has been shown to be effective in increasing muscle
mass and strength, promoting muscle regeneration, and pre-
venting apoptosis (Barton-Davis et al., 1998; Chakravarthy et
al., 2000a; Lawlor and Rotwein, 2000b; Lynch et al., 2001;
Musaro et al., 2001). The results described here show that
muscle-specific IGF-I expression is beneficial to dystrophic
muscle, and, surprisingly, prevents fibrosis in addition to pro-
moting functional hypertrophy. Thus, increasing the rate of
muscle regeneration may be a therapeutic alternative to re-
placing the missing or defective dystrophin complex member
in the dystrophinopathies (Duchenne, Becker, and a subset
of Limb Girdle muscular dystrophies).
Materials and methods
Generation of transgenic animals
IGF transgenic male mice (mIgf
 / ) (Musaro et al., 2001) were bred with
mdx female mice, resulting in a hemizygous F1 generation. Males and fe-
males from this generation were bred, resulting in a group of mice ho-
mozygous for the IGF-I gene and the X-linked mdx mutation. Mice were
screened for the presence of both genes using previously described meth-
ods (Shrager et al., 1992; Barton-Davis et al., 1998; Musaro et al., 2001).
The F2 generation had the expected proportions of homozygosity accord-
ing to Mendelian genetics. Mice exhibiting the desired genotype were bred
to establish homozygotic lines of mdx:mIgf
 /  mice. Mice from the F4 and
subsequent generations were used for analysis.
Muscle morphology
EDL muscles and sections of the anterolateral costal diaphragm were re-
moved from 3- and 14-mo-old mdx:mIgf
 / , mIgf
 / , mdx, and C57Bl/6
(control strain) animals. All muscles were blotted and rapidly frozen in
melting isopentane. EDL muscles were weighed before freezing. 10- m
frozen cross sections taken from the midbelly of the EDLs, and the midsec-
tion of the diaphragms (between the central tendon and ribcage) were
stained with hematoxylin and eosin and Gomori’s trichrome. Stained sec-
tions were visualized on a Leica DMR microscope and captured with a
digital camera using image analysis software (OpenLab). Analysis of fiber
number and size was performed on adjacent sections that had been immu-
nostained for collagen IV (Chemicon International, Inc.) using the same
image analysis software. The fiber numbers at the midbelly of the EDL
were used for comparisons between animals. Fiber numbers across the
sagittal plane of the diaphragms were used as an index of total fiber num-
ber. Fiber areas were assessed in a region containing  500 fibers at the
EDL midbelly and in 500 fibers in each diaphragm. Preliminary measure-
ments confirmed that there was no significant difference between analysis
of 500 fibers in a cross section and that of the entire cross section. Before
morphological analysis, EDL muscles from young mice were analyzed for
functional performance as described below. Total cross-sectional area
(CSA) of EDL muscles was determined using the wet weight and optimum
muscle length (Lo) found during functional assessment in the formula CSA
(mm
2)   muscle mass (mg)/(fiber length/Lo)   (Lo[mm])   1.06 mg/mm
3),
where fiber length/Lo   0.45 (Brooks and Faulkner, 1988).
Muscle mechanical measurements
Isolated whole muscle mechanics was performed on EDL muscles from
3-mo-old mdx:mIgf
 / , mIgf
 / , mdx, and control animals using a previ-
ously described apparatus (Barton-Davis et al., 1998). Lo was defined as the
length that produced maximum twitch tension. Maximum tetanic force at
Lo was measured using a 120 Hz, 500-ms pulse at supramaximal voltage.
Protection against mechanical injury was evaluated by inducing a series of
five eccentric tetanic contractions. These were performed using a 700-ms
stimulation period during which the muscle was held in an isometric con-
traction for the first 500 ms followed by a stretch of 10% Lo at a rate of 0.5
Lo/s. Protection against mechanical injury was evaluated at both 80- and
120-Hz stimulation frequencies. Damage was determined as the loss in
force between the first and last eccentric contraction. At the end of the me-
chanical measurements, muscles were blotted, weighed, and then rapidly
frozen in melting isopentane for subsequent histological analysis as de-
scribed above.
Collagen content
Measures of hydroxyproline were used to assess the amount of fibrosis in
the diaphragms of control, mIgf
 / , mdx, and mdx:mIgf
 /  mice at 14 mo
of age (Amino Acid Analysis). Hydroxyproline content was normalized to
tissue weight for comparisons among muscle samples.
Fiber type composition
Immunohistochemistry was used to determine myosin heavy chain com-
position (Schiaffino and Salviati, 1997). Primary antibody dilutions were as
follows: type I myosin (BA-F8), 1:50; type IIa myosin (SC-71), 1:10; type IIb
myosin (BF-F3), 1:3; embryonic myosin (BF-45), 1:50. FITC-conjugated
goat anti–mouse IgM antibodies and donkey anti–mouse IgG (H   L) (Jack-
son ImmunoResearch Laboratories) were used as secondary antibodies.
Microscopy was performed on a Leitz DMR microscope (Leica). Image ac-
quisition and analysis were performed using a MicroMAX digital camera
system (Princeton Instruments, Inc.) and imaging software (OpenLab).
Evan’s blue staining
Evan’s blue was injected into the tail vein of 3-mo-old mdx:mIgf
 / , and
mdx animals after the procedures previously described (Straub et al. 1997).
Animals were killed 8 h after injection, and muscles were removed and
rapidly frozen in melting isopentane. 10- m frozen sections were fixed in
cold acetone, rinsed in PBS, and covered with aqueous mounting media
containing DAPI nuclear stain (Vectashield; Vector Laboratories). Image
acquisition and analysis were performed as described in the fiber type
composition methodology section.
Immunoblot analysis
Quantification of total Akt, P-Akt, and  -tubulin were determined by West-
ern blotting. Quadriceps muscles from 3-mo-old animals were homoge-
nized in 10 vol/muscle wet weight of modified lysis buffer (50 mM Tris-
HCl, pH 7.4, 1% wt/vol Triton X-100, 0.25% sodium deoxycholate, 150
mM sodium chloride, 1 mM phenylmethylsulfonyl fluoride, 1  g/ml apro-
tinin, 1  g/ml leupeptin, 1  g/ml pepstatin, 1 mM sodium orthovanadate,
1 mM sodium fluoride, 1 mM EGTA). Homogenates were centrifuged to
pellet debris, and the total protein was measured in the supernatant (Bio-
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separated by 12% SDS-PAGE and transferred to polyvinylidene fluoride
membranes (Immobilon-P; Millipore). Membranes were incubated in a
blocking buffer (Tris-buffered saline plus 0.1% Tween 20 that contains 5%
nonfat dry milk [5% milk–TTBS]) and then incubated in primary antibody
diluted in 5% milk–TTBS overnight at 4 C. Membranes were then washed
in 5% milk–TTBS and incubated with HRP-conjugated secondary anti-
body. After a series of washes in 5% milk–TTBS, TTBS, and TBS, protein
detection was performed using ECL and exposure to X-ray film. Analysis of
band intensity was performed using image analysis software (Kodak 1D;
Eastman Kodak Co.) on the scanned films. Membranes were stained with
Coomassie brilliant blue R-250 after immunoblotting to confirm equal pro-
tein loading. Antibodies and the conditions used in these measurements
were as follows: rabbit anti–phospho-Akt (Ser473), 1:700 (Cell Signaling
Technology); rabbit anti–phospho-Akt (Thr308), 1:700 (Cell Signaling
Technology); sheep anti-Akt1, 1:300 (Upstate Biotechnology); HRP–anti-
rabbit, 1:2,000 (Cell Signaling Technology); HRP–anti-sheep, 1:2,000
(Binding Site).
Statistics
Unpaired t tests were used for comparisons between age-matched control
and mIgf
 / , mdx:mIgf
 / , and mdx muscles, and between mdx and mdx:
mIgf
 /  muscles. Statistical significance was accepted for comparisons
where P   0.05.
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